// App-Quantinova.ai

DOP002 : Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS study

Researchers

Presenter

  • S Vermeire

Principal Investigators

  • E V Loftus Jr

  • J M Khalid

  • D Tudor

  • M Akbari

  • D Demuth

  • L Peyrin-Biroulet

Medical Centers

  • Katholieke Universiteit Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium

  • Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

  • Takeda Pharmaceuticals International Co., Cambridge, MA

  • Nancy University Hospital, Lorraine University, Department of Gastroenterology, Nancy, France

Locations

  • Belgium

  • United States

  • United Kingdom

  • Switzerland

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved